Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model - Fierce Biotech

Ah, another day, another nine-figure cheque from the Alphabet gravy train. Isomorphic Labs has just hoovered up $2.1 billion in Series B funding to flog its AI drug design engine, IsoDDE. Because nothing says 'revolutionary biotech breakthrough' like a round that could fund a small country's GDP. The press release, no doubt, will promise to 'accelerate the drug pipeline' and 'transform how we discover medicines' — we've heard this exact script from every AI-drug startup since 2016. What's different this time? The parent company's ability to write a bigger cheque before the inevitable 'we need more data' pivot.

Let's not be churlish — $2.1 billion does buy a lot of compute and a lot of PhDs. But IsoDDE is not a drug; it's a model. A model that will generate plausible-looking molecules that still need to survive Phase I, Phase II, Phase III, and the tender mercies of the FDA. The gap between 'AI suggests a protein-ligand interaction' and 'drug approved for humans' is measured in years, not API calls. Yet the valuation implied by this round suggests someone believes the gap is measured in PowerPoint slides.

And here's the kicker: Isomorphic Labs is an Alphabet subsidiary, so the real money has been there all along. This Series B is effectively an internal transfer with added PR fireworks. The actual test won't come until IsoDDE spits out a compound that actually works in a human trial. Until then, it's just the latest shiny object in the world's most well-funded sandbox. Enjoy the champagne, lads — the FDA's rejection letters are drafted.